Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs

Vaccine. 1999 May 4;17(18):2229-36. doi: 10.1016/s0264-410x(99)00009-2.

Abstract

The ability of a genetically detoxified mutant of heat labile enterotoxin (LTK63) to act as a mucosal adjuvant following intranasal immunization with recombinant gD2 has previously been reported in mice [Ugozzoli M, O'Hagan DT, Ott GS. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunol 1998;93:563-571.]. In the current studies, these observations were extended to the guinea pig model. Immunized guinea pigs were subsequently challenged intravaginally with HSV-2. Intranasal immunization with gD2 and LTK63 induced a significant reduction in disease severity and a reduction in mortality. However, only intramuscular immunization with a potent adjuvant (MF59) induced protection against the incidence of disease.

MeSH terms

  • Administration, Intranasal
  • Animals
  • Female
  • Guinea Pigs
  • Herpes Genitalis / mortality*
  • Herpes Genitalis / prevention & control*
  • Herpesvirus 2, Human / immunology*
  • Recombinant Proteins / administration & dosage*
  • Recombinant Proteins / immunology
  • Recombinant Proteins / therapeutic use
  • Viral Envelope Proteins / administration & dosage*
  • Viral Envelope Proteins / immunology
  • Viral Envelope Proteins / therapeutic use
  • Viral Vaccines / administration & dosage*
  • Viral Vaccines / immunology
  • Viral Vaccines / therapeutic use

Substances

  • Recombinant Proteins
  • Viral Envelope Proteins
  • Viral Vaccines
  • glycoprotein D-herpes simplex virus type 2